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Abstract
Objectives: Calcium independent group VIA phospholipase A2 (iPLA2b) is up-regulated in vascular smooth muscle cells in
some diseases, but whether the up-regulated iPLA2b affects vascular morphology and blood pressure is unknown. The
current study addresses this question by evaluating the basal- and angiotensin II infusion-induced vascular remodeling and
hypertension in smooth muscle specific iPLA2b transgenic (iPLA2b -Tg) mice.
Method and Results: Blood pressure was monitored by radiotelemetry and vascular remodeling was assessed by
morphologic analysis. We found that the angiotensin II-induced increase in diastolic pressure was significantly higher in
iPLA2b-Tg than iPLA2b-Wt mice, whereas, the basal blood pressure was not significantly different. The media thickness and
media:lumen ratio of the mesenteric arteries were significantly increased in angiotensin II-infused iPLA2b-Tg mice. Analysis
revealed no difference in vascular smooth muscle cell proliferation. In contrast, adenovirus-mediated iPLA2b overexpression
in cultured vascular smooth muscle cells promoted angiotensin II-induced [3H]-leucine incorporation, indicating enhanced
hypertrophy. Moreover, angiotensin II infusion-induced c-Jun phosphorylation in vascular smooth muscle cells
overexpressing iPLA2b to higher levels, which was abolished by inhibition of 12/15 lipoxygenase. In addition, we found
that angiotensin II up-regulated the endogenous iPLA2b protein in-vitro and in-vivo.
Conclusion: The present study reports that iPLA2b up-regulation exacerbates angiotensin II-induced vascular smooth
muscle cell hypertrophy, vascular remodeling and hypertension via the 12/15 lipoxygenase and c-Jun pathways.
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Introduction
Phospholipase A2 is a large family of enzymes that catalyze the
hydrolysis of the sn-2 ester bond on phospholipids to produce free
fatty acids (e.g., arachidonic acid) and lysophospholipids [1]. Calcium
independent group VIA phospholipase A2 (iPLA2b), a member of
the phospholipase A2 superfamily, is an intracellular protein that is
catalytically active in the absence of calcium [1]. iPLA2b was initially
implicated as a housekeeping enzyme in phospholipid remodeling;
however, accumulating evidence indicates that it also plays
fundamental roles in cellular signaling, causing cell activation,
proliferation, migration or apoptosis [1]. Moreover, iPLA2b plays a
significant role in a variety of diseases including neurodegenerative
disorders [2,3], cardiac ischemia induced arrhythmia [4,5,6] and
tumor genesis and metastasis [7,8]. However, whether iPLA2b is
involved in hypertension remains unreported.
An estimated 29% of the United States adult (.18 years of age)
population is hypertensive, exposing these individuals to an increased
risk of mortality and cardiovascular events over their lifespan [9].
The mechanisms underlying primary hypertension remain incom-
pletely understood. Evidence obtained from studies on cultured cells
or isolated tissues demonstrates that iPLA2b is involved in the
regulation of multiple vascular smooth muscle functions and thus
may contribute to hypertension and associated vascular remodeling.
We [10,11] and others [12,13,14] have demonstrated that iPLA2b
plays an important role in vascular smooth muscle contraction
regulation. Inhibition of iPLA2b by the selective suicidal iPLA2
inhibitor BEL, anti-sense oligonucleotides or genetic deletion
drastically inhibit arachidonic acid release induced by vasopressin
[15], thrombin [16], and thapsigargin/A23187 [17]. Moreover,
inhibition or genetic deletion of iPLA2b significantly reduce
thrombin-induced DNA synthesis [16] and smooth muscle migra-
tion and proliferation, which was analyzed in isolated mesentery
artery tissue in an explant assay [17], suggesting that iPLA2b is
involved in smooth muscle migration and proliferation. Together,
these data imply that vascular smooth muscle iPLA2b is pro-
hypertensive. On the other hand, iPLA2b is also required for
angiotensin II (Ang II) induced RGS2 transcription in vascular
smooth muscle cells (VSMC) [18] and deleting iPLA2b promotes
vascular constriction [14]. Since RGS2 is a negative regulator of Ang
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II-induced hypertension, these imply vascular smooth muscle
iPLA2b can also be anti-hypertensive. Taken together, the precise
role that vascular smooth muscle iPLA2b plays in hypertension and
vascular remodeling in vivo remains to be determined.
The activity of iPLA2b is regulated at multiple levels including
allosteric interaction with ATP [19] or calmodulin [20], covalent
modification by acylation [21], and potentially by proteolysis and
translocation [22]. Interestingly, recent evidence suggests that, in
addition to post-translational regulation, the iPLA2b protein level
is up-regulated under various pathological conditions; the mRNA
and protein are up-regulated in Type 1 diabetic Akita mouse
pancreatic cells [23], in astrocytes stimulated with pro-inflamma-
tory lipopolysaccharide [24] and in C2C12 myotubes by ischemia
[6]. In particular, we have found that iPLA2b is up-regulated in
VSMC cultured in the presence of high glucose, and is up-
regulated in the vasculature from streptozotocin-induced hyper-
glycemic rats or Type 2 diabetic db/db mice [11]. However,
whether the up-regulated iPLA2b, among the numerous alter-
ations present under these pathological conditions contributes to
hypertension and vascular remodeling is unknown.
We have developed a smooth muscle specific iPLA2b transgenic
mouse model to determine whether up-regulated iPLA2bmodulates
Ang II infusion-induced hypertension and vascular remodeling. Ang
II is the major bioactive peptide of the renin-angiotensin-aldosterone
system and its dysregulation is one of the major factors contributing
to the pathogenesis of hypertension. Chronic subcutaneous infusion
of Ang II induces hypertension and vascular remodeling and has
been used extensively as a model to decipher the mechanisms
underlying hypertension. Our in-vivo and in-vitro studies demonstrate
that vascular smooth muscle iPLA2b up-regulation exacerbates Ang
II-induced hypertension and vascular remodeling.
Methods
Ethics Statement
All animal work has been conducted according to relevant
national and international guidelines. Animal protocols used in the
study were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Kentucky, approved ID
00920M2005.
Animals
Smooth muscle specific overexpressing iPLA2b transgenic mice
(iPLA2b-Tg) were generated, characterized, and backcrossed to
C57/B6 for over 10 generations as described elsewhere (Liu et.al.,
manuscript submitted). The expression of iPLA2b is driven by a
rabbit smooth muscle myosin heavy chain promoter. The 12/15
lipoxygenase knockout mice were purchased from The Jackson
Laboratory.
Materials
Ang II was purchased from Sigma (St. Louis, MO). 17-
Octadecynoic acid, MK886, Baicalein, and Luteolin were
purchased from Cayman (Ann Arbor, MI). Nordihydroguaiaretic
acid and Indomethacin were purchased from Biomol (Plymouth
Meeting, PA). The primary antibodies to b-actin, phospho-c-Jun,
phospho-p38 MAPK, total-p38 MAPK were purchased from Cell
Signaling (Danvers, MA). The iPLA2b antibody was made in our
lab, and the generation and characterization of the antibody was
previously documented [18].
Primary Cell Culture
Aortic VSMC were isolated from 12–13 wk old rats or mice and
used at passages 5 to 10 as previously described [25].
Western Blot
After the indicated treatments, cells were collected, lysates were
prepared, and the proteins were separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to nitrocellulose
membranes, which were then western blotted with the following
antibodies: iPLA2b (1:2500), b-actin (1:2500), phospho-c-Jun
(1:1000), phospho-p38 MAPK (1:2000), total-p38 MAPK
(1:2000), respectively. The proteins were quantified using the
ECL Plus Western Blotting Detection System (GE Healthcare).
Blood Pressure Measurement
Eight pairs of 13-wk old male iPLA2b-Tg and iPLA2b-Wt
(littermate) mice were anesthetized with isoflurane and implanted
with telemetry probes (TA11PA-C10, Data Sciences International,
St. Paul, MN) in the left carotid artery. After 7 to 10 days of
recovery, basal blood pressure, heart rate, and locomotor activity
data were collected continuously using the Dataquest A.R.T.
system (Data Sciences International, St. Paul, MN) for 72 h.
Osmotic mini-pumps (Alzet Model 2002) were then implanted,
subcutaneously, to infuse Ang II (500 ng/kg/min, 14 days) or
saline. During the infusion period, blood pressure data was
collected continuously for 24 h every other day.
Morphometric Analysis of Vascular Remodeling
At the 14th day of Ang II or saline infusion, the mice were
euthanized and perfused under physiological pressure with PBS
and 4% paraformaldehyde. Thoracic aortas (2 mm from descend-
ing aorta) and secondary branches of the mesenteric arteries were
isolated, cleaned, embedded, and cut into 5 mm sections. Sections
were stained with HE (Hematoxylin-Eosin, Surgipath), or Elastin
(Elastin Stain kit, Richard-Allan Scientific), or collagen (Masson
Trichrome Stain, Richard-Allan Scientific). Images were captured
and analyzed using an Olympus digital camera with Olympus
MicroSuit-B3 Software. Elastin stained slides were used for
morphometric analysis. The media thickness was determined by
measuring the distance from the internal elastic lamina (IEL) to the
external elastic lamina (EEL). For each slide, measurements from 4
points (12, 3, 6 and 9 o’clock positions) were averaged. The media
area was determined by measuring the area between the IEL and
EEL. The media:lumen ratio was calculated based on the
measured lumen area and media areas.
Immunohistochemistry
Slides with paraffin embedded vascular sections were antigen
retrieved (Low pH antigen retrieve buffer, Vector laboratory), and
then treated with 3% hydrogen peroxide for 20 min to quench the
endogenous peroxidases. After blocking the endogenous biotin
(Avidin/Biotin blocking kit, Vector Laboratory), the slides were
blocked with normal goat serum (Vectastain ABC Kit) for 1 h and
were incubated overnight at 4uC with anti-iPLA2b (1:5000) or
anti-Proliferating Cell Nuclear Antigen antibody (1:15000)
(PCNA, Cell signaling technology). The slides were then incubated
with secondary antibodies, washed, incubated with the Avidin-
Biotin-Peroxidase complex (Vector Laboratories) for 30 min,
washed, and stained with DAB (DAKO) and counter stained with
hematoxylin (Surgipath). Images were taken using an Olympus
1670 microscope.
OCT embedded 2nd order mesentery artery branches were
sectioned and fixed for 30 min in paraformaldehyde. Sections
were blocked with normal goat serum and incubated with anti-p-c-
Jun (1:100). Slides were then washed, incubated in fluorescently-
labeled (1:200, Alexa-Fluor 594, Invitrogen) secondary antibodies
and counterstained with DAPI (300 nM).
iPLA2b in Angiotensin II-Induced Hypertension
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iPLA2b Adenoviral Infection
The doxycycline-inducible iPLA2b-expressing adenoviral vec-
tors were generated and purified as previously described [10].
Serum starved cells were infected for 12 h with Ad-iPLA2b (500
MOI) and Ad-Tet-on (2000 MOI). Doxycyclin (1 mg/ml) was
added to the culture medium for 24 h to induce iPLA2b
expression. The cells were then harvested for iPLA2b protein
expression analysis or used for [3H]-leucine incorporation assay.
[3H]-Leucine Incorporation
After the indicated treatment, the VSMC were incubated with
[3H]-leucine (0.25 mCi/well) for 24 h, washed, harvested and
[3H]-leucine incorporation was quantified by liquid scintillation
spectroscopy (Packard, Packard BioScience Company) as previ-
ously described [26].
Statistical Analysis
Each experiment was repeated a minimum of three times. Data
were expressed as mean 6 S.E. Statistical analysis was performed
by using one- and/or two-way analysis of variance with repeated
measurement for multiple groups. A post-hoc Bonferroni analysis
was performed when appropriate (GraphPad Prism 4). Statistical
significance was set at p,0.05.
Results
Smooth muscle specific iPLA2b overexpression
exacerbates Ang II infusion-induced hypertension
without affecting basal blood pressure
To examine the role of iPLA2b in basal blood pressure and in
Ang II-induced hypertension, we utilized the smooth muscle specific
iPLA2b-Tg mice that we previously developed (Liu et.al.,
manuscript submitted). No significant difference was detected in
basal systolic (Fig. 1A); diastolic (Fig. 1B) or mean arterial blood
pressure (Fig. 1C) between the iPLA2b-Tg and iPLA2b-Wt mice.
Ang II infusion (500 ng/kg/min, 14 days) rapidly increased systolic,
diastolic, and mean arterial pressure in both strains (Fig. 1A–C);
saline infusion did not affect these parameters (Data not shown).
Interestingly, diastolic pressure after Ang II infusion was signifi-
cantly higher in iPLA2b-Tg mice (11568.6 mmHg) than in the
iPLA2b-Wt mice (107610.3 mmHg) (Fig. 1B). Both the systolic and
mean arterial pressures were higher in the iPLA2b-Tg mice after
Ang II infusion, but the difference did not reach statistical
significance. Additionally, no difference in the heart rate or pulse
pressure was detected and the locomoter activity was lower in the
iPLA2b-Tg mice than the iPLA2b-Wt mice (Fig. 1D–F).
Vascular remodeling induced by Ang II infusion is
exacerbated in iPLA2-Tg mice
To investigate the mechanism underlying the exacerbation of Ang
II infusion-induced blood pressure elevation in iPLA2b-Tg mice, we
used morphometric analysis to determine whether iPLA2b overex-
pression affects Ang II-induced vascular remodeling. In the
mesenteric arteries, iPLA2b overexpression alone did not signifi-
cantly alter mesenteric artery collagen or elastin expression (Fig. 2A).
However, iPLA2b overexpression significantly promoted the Ang II
infusion-induced increase in media thickness (Fig. 2B) and media:lu-
men ratio (Fig. 2C). In the thoracic aorta, iPLA2b overexpression
also significantly promoted Ang II infusion-induced increases in
media thickness (Fig. 3B) without altering the media:lumen ratio
(Fig. 3C) and the elastin or collagen expression (Fig. 3A).
iPLA2b overexpression enhances Ang II-induced vascular
remodeling by promoting vascular smooth muscle
hypertrophy via the 12/15 lipoxygenase pathway
To elucidate the mechanism via which iPLA2b enhances Ang
II-induced vascular remodeling, we investigated the effects of
iPLA2b overexpression on VSMC proliferation and hypertrophy.
Figure 1. Enhanced diastolic blood pressure increase in iPLA2b-Tg mice in response to Ang II infusion. Blood pressure was measured in
13-wk old male, iPLA2b-Wt and iPLA2b-Tg mice by radiotelemetry. 24 h averages of systolic (A), diastolic (B), and mean arterial pressure (C), heart rate
(D), pulse pressure (E), and locomotor activity (F) were collected prior to and during Ang II infusion (500 ng/kg/min, 14 days). n = 8; *: p,0.05 by two-
way ANOVA with repeated measures.
doi:10.1371/journal.pone.0031850.g001
iPLA2b in Angiotensin II-Induced Hypertension
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The proliferation state was assessed by PCNA staining and cell
counting. No significant difference was detected in PCNA staining
[aorta (Fig. 4A) or mesentery artery (data not shown)] or cell
number [aorta and mesentery artery (Fig. 4B,C)].
Next, we examined the effect of iPLA2b overexpression on Ang
II-induced vascular smooth muscle hypertrophy in cultured VSMC.
We found that exogenous overexpressed iPLA2b was gradually lost
during the passage of VSMC isolated from the iPLA2b-Tg mice;
therefore, we overexpressed iPLA2b by doxycycline inducible
adenoviral vector mediated gene transfer as previously described
[11,18] and achieved an 11-fold increase in iPLA2b protein
expression (data not shown). Ang II-induced [3H]-leucine incorpo-
ration was significantly enhanced by iPLA2b overexpression to 1.73-
fold (Fig. 5A). As a control, neither doxycycline nor adenovirus
treatment alone had an effect on the basal [3H]-leucine incorpo-
ration (Fig. 5A). Together, these results suggest that iPLA2b
overexpression facilitates VSMC hypertrophy.
To dissect the mechanism downstream of iPLA2b that
exacerbates Ang II-induced VSMC hypertrophy, we examined
the role of the arachidonic acid metabolites from lipoxygenase,
cyclooxygenase or P450 pathways on [3H]-leucine incorporation.
The inhibition of lipoxygenase by NDGA nearly abolished both
basal and Ang II-induced [3H]-leucine incorporation (Fig. 5B),
whereas, inhibition of cyclooxygenase by Indomethacin had no
effect. P450 inhibition by ODA significantly attenuated Ang II-
stimulated [3H]-leucine incorporation (Fig. 5B). VSMC isolated
from 12/15 lipoxygenase knockout (lox2/2) mice also showed a
significant attenuation of Ang II stimulated [3H]-leucine incorpo-
Figure 2. Exacerbated mesenteric artery remodeling in iPLA2b-Tg mice in response to Ang II infusion. Vascular remodeling was analyzed
in embedded sections of the 2nd order branch of mesenteric arteries from the iPLA2b-Wt and iPLA2b-Tg mice infused with saline or Ang II (500 ng/kg/
min, 14 days). Representative images of vessel sections stained with HE, elastin or collagen (A). The media thickness (B) and media:lumen ratio (C)
were quantified. n = 8, *: p,0.05, **: p,0.01, ***: p,0.001 by one-way ANOVA.
doi:10.1371/journal.pone.0031850.g002
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ration (Fig. 5C), verifying the essential role of iPLA2b and the 12/
15 lipoxygenase pathway in Ang II-induced VSMC hypertrophy.
iPLA2b overexpression promotes Ang II-induced c-Jun
phosphorylation via the 12/15 lipoxygenase metabolites
c-Jun phosphorylation has been demonstrated to be required for
Ang II-induced VSMC hypertrophy. We therefore further
investigated whether iPLA2b overexpression exacerbates Ang II-
induced c-Jun phosphorylation by immunohistochemistry using
mesentery artery sections from iPLA2b-Wt and iPLA2b-Tg mice.
Ang II infusion enhanced the staining in both the iPLA2b-Wt and
iPLA2b-Tg mouse sections (Fig. 6A). Moreover, the staining in the
iPLA2b-Tg mice was much higher than that in the iPLA2b-Wt
mice (Fig. 6A), indicating that iPLA2b overexpression promotes
Ang II infusion-induced c-Jun phosphorylation.
To further clarify the mechanism downstream of iPLA2b, we
examined the role of the arachidonic acid metabolites in Ang II-
induced c-Jun phosphorylation. The results demonstrate that
inhibition of lipoxygenase by NDGA, but not inhibition of
cyclooxygenase by indomethacin or P450 by ODA significantly
attenuated Ang II-induced c-Jun phosphorylation (Fig. 6B, C). A
significant attenuation of Ang II-stimulated c-Jun phosphorylation
was also observed in VSMC isolated from 12/15 lipoxygenase
knockout (lox2/2) mice (Fig. 6D, E), indicating a critical role of
the 12/15 lipoxygenase pathway in Ang II-induced VSMC
hypertrophy. Interestingly, the Ang II-induced p38 MAPK
Figure 3. Exacerbated thoracic aorta remodeling in iPLA2b-Tgmice in response to Ang II infusion. Vascular remodeling was analyzed in the
thoracic aorta of the iPLA2b-Wt and iPLA2b-Tg infused with Ang II (500 ng/kg/min) or saline. Representative images of vessel sections stained with HE,
elastin or collagen (A). The media thickness (B) and media:lumen ratio (C) were quantified. n = 8, **: p,0.01, ***: p,0.001 by one way ANOVA.
doi:10.1371/journal.pone.0031850.g003
iPLA2b in Angiotensin II-Induced Hypertension
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phosphorylation was not affected by any of the arachidonic acid
metabolism enzyme inhibitors tested (Fig. 7A, B).
Ang II increases endogenous iPLA2b protein expression
in VSMC
To further explore a possible role of endogenous iPLA2b in Ang
II’s effects, we determined whether iPLA2b protein is up-regulated
by Ang II in-vitro and in-vivo. In cultured iPLA2b-Wt VSMC, Ang
II treatment significantly increased iPLA2b protein expression
within the time frame from 3 h to 48 h (Fig. 8A–B). In-vivo, Ang II
infusion enhanced iPLA2b protein expression in the thoracic aorta
as indicated by immunohistochemical analysis (Fig. 8C, note
brown color accumulation in the media layer).
Discussion
In the present study, we investigate the role of up-regulated
smooth muscle iPLA2b in Ang II-induced VSMC hypertrophy,
vascular remodeling and hypertension. Several novel findings are
reported here. First, using a smooth muscle specific iPLA2b-Tg
mouse model, we find that overexpression of iPLA2b in smooth
muscle exacerbates Ang II infusion-induced blood pressure
Figure 4. Lack of difference in cell proliferation between iPLA2b-Tg and iPLA2b-Wt mice by Ang II infusion. Mice were infused with
saline or Ang II (500 ng/kg/min, 14 days) and thoracic aortas were isolated and sectioned. (A) are representative images of the sections stained with
anti-PCNA antibody. (B) and (C) are summaries of the cell number analysis using HE stained sections. n = 8.
doi:10.1371/journal.pone.0031850.g004
Figure 5. iPLA2b overexpression promotes Ang II-induced [
3H]-leucine incorporation in VSMC via the 12/15 lipoxygenase pathway.
[3H]-leucine incorporation was quantified by liquid scintillation spectroscopy in cultured iPLA2b-Wt VSMCs treated with Ang II (100 nM, 24 h) or saline
after (A) Ad-iPLA2b (500 MOI) and Ad-tet-on (2000 MOI), and/or doxycycline (1 mg/ml); (B) saline or inhibitors of lipoxygenase (NDGA, 30 mM), or
cyclooxygenase (Indomethacin, 50 mM) or P450 cytochrome C (ODA, 10 mM). (C) Lox2/2 or Wt VSMCs stimulated with Ang II or saline. n = 3–4,
*: p,0.05, **: p,0.01, ***: p,0.001 one-way ANOVA.
doi:10.1371/journal.pone.0031850.g005
iPLA2b in Angiotensin II-Induced Hypertension
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Figure 6. iPLA2b overexpression promotes Ang II-induced c-Jun phosphorylation via the 12/15 lipoxygenase pathway. (A) iPLA2b-Wt
and iPLA2b-Tg mice were infused with Ang II (1000 ng/kg/min, 14 days) or saline and 2
nd order branch of mesenteric arteries VSMC were isolated and
embedded in OCT. Vessel sections were stained with anti-p-c-Jun antibody and DAPI. (B) and (D) are representative western blots, (C) and (E) are
quantifications of the blots, of c-Jun phosphorylation in aortic VSMCs after the same treatments as in Fig. 3 B and C. n = 3–4, *:p,0.05, **: p,0.01,
***: p,0.001 one-way ANOVA.
doi:10.1371/journal.pone.0031850.g006
iPLA2b in Angiotensin II-Induced Hypertension
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increase and vessel remodeling. Second, we demonstrate that the
up-regulated iPLA2b acts via the 12/15 lipoxygenase pathway to
induce c-Jun phosphorylation and to promote Ang II-induced
VSMC hypertrophy. Third, Ang II up-regulates iPLA2b protein in
cultured VSMCs and in-vivo during Ang II-infusion.
Metabolites of free arachidonic acid produced by the three
major pathways, cyclooxygenase [27,28], lipoxygenase [29,30]
and cytochrome P450 [31] have been demonstrated to play a role
in hypertension. Different classes of phospholipase A2 may be
responsible for the release of arachidonic acid, which is rate-
limiting. Among these phospholipases, the cytosolic calcium-
dependent cPLA2 has been shown to play an important role in the
development of hypertension induced by chronic NO inhibition
[32]. However, to the best of our knowledge, whether the cytosolic
calcium-independent phospholipase A2, iPLA2b, participates in
hypertension has not been reported. The current study for the first
time demonstrates that iPLA2b overexpression in smooth muscle
does not alter basal blood pressure, but exacerbates Ang II
infusion induced hypertension and vascular remodeling. The lack
of effect on basal blood pressure by iPLA2b overexpression is likely
due to the fact that under resting conditions iPLA2b is presumably
bound to calmodulin thus catalytically inactive [13]. Upon Ang II
stimulation, iPLA2b is dissociated from calmodulin and activated
therefore exacerbating Ang II infusion-induced blood pressure
increase. Several lines of evidence suggest that the enhanced Ang
II infusion-induced blood pressure increase is specifically caused
by iPLA2b overexpression in vascular smooth muscle. First,
neither the locomotor activity nor heart rate is increased in the
iPLA2b-Tg mice (Fig. 1D, F), suggesting that locomotor activity
and heart rate are not responsible for the exaggerated increase in
blood pressure in response to Ang II-infusion. Second, among the
diastolic, systolic and mean arterial pressure, the diastolic pressure
exhibited the most enhancement by iPLA2b overexpression (Fig. 1).
It is established that enhanced diastolic pressure is associated with
an increase in peripheral resistance, whereas, enhanced systolic
pressure is reliant on an increase in large conduit vessel stiffness
and stroke volume [33]. The selective diastolic pressure enhance-
ment observed in iPLA2b-Tg mice, in response to Ang II infusion,
suggests that it is the increase in resistance of the vasculature that
accounts for the enhanced blood pressure response. Third,
morphometric analysis of the mesentery arteries reveals that the
media thickness and media:lumen ratio are significantly increased
in the iPLA2b-Tg. This enhanced vessel remodeling in small
arteries is expected to increase peripheral resistance and thus
contributes to the enhanced diastolic blood pressure observed in
the iPLA2b-Tg mice. Finally, the systolic blood pressure was
similar in the iPLA2b-Tg and control mice. This is consistent with
the observation that there was no significant difference in the aorta
elastin and collagen content, which implies that the stiffness of the
conduit vessels is similar in the iPLA2b-Tg and iPLA2b-Wt mice.
Phospholipase A2 and arachidonic acid metabolites are involved
in hypertension caused by various mechanisms; however, it is
interesting to note that blood pressure under basal physiological
Figure 7. Lack of effects of inhibiting arachidonic acid
metabolism on Ang II induced p38 MAPK activation. VSMC
were isolated from the aortas of iPLA2b-Wt mice and incubated with
inhibitors of lipoxygenase (NDGA, 30 mM), cyclooxygenase (Indometh-
acin, 50 mM) or P450 cytochrome C (ODA, 10 mM) and stimulated with
Ang II (100 nM) or saline for 1 h. Then the total- or phosphorylated p38
MAPK was determined by Western Blot. n = 3–4.
doi:10.1371/journal.pone.0031850.g007
Figure 8. Ang II enhances iPLA2b protein expression in cultured
VSMC and in-vivo. 24 h serum-deprived rat aortic VSMC were
stimulated with Ang II (100 nM) for various time intervals as indicated.
iPLA2b protein abundance was determined by Western Blot (A and B).
Representative immunohistochemical images of iPLA2b protein staining
in C57/B6 thoracic aorta from iPLA2b-Wt and iPLA2b-Tg mice infused
with saline or Ang II (500 ng/kg/min, 14 days) (C). n = 4–5; *: p,0.05 by
one-way ANOVA analysis.
doi:10.1371/journal.pone.0031850.g008
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conditions was not affected by iPLA2b smooth muscle overex-
pression (present study), or by deleting cPLA2 [34] or 12/15
lipoxygenase [30]. This suggests that the arachidonic acid
metabolites do not alter basal blood pressure homeostasis, but
play a significant role in pathological hypertension induced by Ang
II infusion (present study), renal artery occlusion, or blockade of
NO [30,35]. These observations raise the possibility that the
phospholipase A2/arachidonic acid pathway is a therapeutic target
for selective lowering of blood pressure under pathological
conditions without disturbing normal physiological blood pressure.
The exacerbation of vascular remodeling in iPLA2b-Tg mice
can be a consequence in response to increased blood pressure or
an enhancement of Ang II’s direct effect on vasculature. Our
results suggest that increasing iPLA2b enhances Ang II signaling in
the vasculature. In cultured VSMC, we found that iPLA2b
overexpression enhanced Ang II-induced [3H]-leucine incorpora-
tion, indicating promotion of Ang II’s direct effects on VSMC
account for, at least in part, the exacerbation of vascular
remodeling. Increased VSMC proliferation and/or hypertrophy
may underlie the enhanced vascular remodeling. Our results
demonstrate selectively enhanced hypertrophy in the absence of
detectable alterations of proliferation in both mesenteric arteries
and descending aortas in iPLA2b-Tg mice. This further suggests
that iPLA2b overexpression amplifies Ang II mediated hypertro-
phic pathways and is consistent with the observations of others
who found that Ang II selectively induces hypertrophy in cultured
VSMCs [36] and in-vivo in the descending aorta [37].
Among the elaborate signaling network activated by Ang II, the
lipoxygenase [38], c-Jun NH2-terminal kinase (JNK) [39] and p38
MAPK [40] pathways are known to be essential mediators of Ang
II induced VSMC hypertrophy. This study demonstrates that
iPLA2b overexpression potentiates Ang II-induced VSMC hyper-
trophy via activation of the lipoxygenase pathway since [3H]-
leucine incorporation was inhibited by NDGA (Fig. 5B) or by
genetic deletion of 12/15 lipoxygenase (Fig. 5C). Interestingly,
only the JNK activation, as indicated by increased c-Jun
phosphorylation (Fig. 6B–E), but not p38 MAPK (Fig. 7A,B) is
affected by inhibition of the 12/15 lipoxygenase pathway. This is
consistent with the report that p38 MAPK is upstream of and
required for iPLA2b activation induced by thrombin [16].
In addition to iPLA2, cPLA2 has been shown to be activated by
Ang II [41,42] and is required for Ang II-induced arachidonic acid
release [43] and hypertrophy [44] in VSMC. The relationship
between the cPLA2 and iPLA2 in the regulation of arachidonic
acid release and cell hypertrophy remain to be established. It is
conceivable that iPLA2 and cPLA2 act in a sequential manner.
iPLA2 has been demonstrated to play a critical role in store-
operated calcium influx [45] and that is crucial for cPLA2a
activation [35]. Indeed, iPLA2 has been shown to mediate the
early phase whereas cPLA2 mediates the late phase of arachidonic
acid release in response to thapsigargin and ionophore A23187 in
VSMCs [17].
Emerging evidence suggests that iPLA2b protein level is
increased under disease conditions including ischemia [6], Type
I diabetes mellitus in pancreatic b-cells [23] and vascular tissues
[11], in addition to being regulated by complex post-translational
modifications. Whereas, thrombin activation of iPLA2 is not
associated with iPLA2 protein level alterations [16], the current
study demonstrates that Ang II activation of iPLA2b is associated
with up-regulation of iPLA2b protein in cultured VSMC and in-
vivo in the vascular tissue (Fig. 8A–C). This is the first evidence that
a G-protein-coupled-receptor agonist can up-regulate iPLA2b
protein, suggesting that the regulation of iPLA2b protein is agonist
specific. However, whether iPLA2b protein up-regulation is
required for Ang II infusion induced hypertension requires further
investigation using iPLA2b knockout mice.
In summary, the present study is the first to demonstrate a novel
role of up-regulated vascular smooth muscle iPLA2b in Ang II-
induced hypertension, vascular remodeling and VSMC hypertro-
phy. This effect of iPLA2b is mediated via the lipoxygenase
pathway, which induces JNK activation. Ang II stimulation up-
regulates iPLA2b protein expression and these results suggest that
up-regulated iPLA2b has significant effects on the vasculature.
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